Press release

Press release

August 2, 2017

Follicum successfully completes its Phase I / IIa clinical study of FOL-005 and prepares for a Phase II clinical study

Follicum AB (“Follicum”) has now obtained the final results from the completed phase I / IIa clinical study. The results after a three-month follow-up period following the completion of treatment with FOL-005, demonstrate that the rate of hair growth does return to its original level. The results thereby confirm that Follicum’s drug candidate FOL-005 stimulates […]

April 18, 2017

Follicum’s Clinical Study Shows Stimulation of Hair Growth

Follicum AB hereby announces that the FOL-005 study at the Charité hospital in Berlin, Germany, has shown a stimulation of hair growth in treatment of healthy volunteers. In February 2017, Follicum is able to announce that the company’s phase I/IIa clinical study of the FOL-005 candidate drug showed a good safety profile, and that no […]

April 5, 2017

Notice of Annual General Meeting

The shareholders of Follicum AB (publ), 556851-4532, are invited to the Annual General Meeting,  on Wednesday the 26 April 2017 at 16.00 (4.00 p.m.) (CEST), at Scheelevägen 22, Lund. Full invitation and agenda of the AGM in Swedish For further information, please contact: Jan Alenfall, CEO Phone: +46 (0) 46 19 21 97 E-mail: info@follicum.com

April 5, 2017

Annual Report 2016 available

Follicum AB’s Annual Report for 2016 has now been published in Swedish. Annual Report 2016 (in Swedish) For more information,  please contact: Jan Alenfall, CEO Tel: +46 (0)46 19 21 97 Email: info@follicum.com

January 12, 2017

Follicum patent approved in Japan

Follicum AB announced on 9 January that the Japanese Patent Office (“JPO”) issued approval for the company’s patent application regarding the stimulation of hair growth. Thanks to this approval from the JPO, Follicum has protection in Japan for the company’s peptides in general and for the stimulation of hair growth specifically. The patent number is […]

January 12, 2017

Follicum patent approved in Russia

Follicum AB announced on 4 January that the Russian Patent Office  (“ROSPATENT”) issued approval for the company’s patent application regarding the stimulation of hair growth. Thanks to this approval from ROSPATENT, Follicum has protection in Russia for the company’s peptides in general and for the stimulation of hair growth specifically. The patent number is 2604797 […]

November 25, 2016

Q3 2016 Interim Report published

The Interim Report for Q3 2016, covering the period from   1 January 2016 to 30 September 2016, has now been published in Swedish. Read the full report here (in Swedish only)

November 23, 2016

Follicum’s clinical phase I/IIa study to be completed in January 2017

The multiple dose part of Follicum’s clinical phase I / II a study on candidate drug FOL-005, being conducted at the Charité University Hospital in Berlin, is expected to complete in January 2017 rather than before Christmas 2016, as previously announced. This multiple dose part of the study, in which two groups are treated with […]

August 26, 2016

2016 Half-year Report published

Follicum has today published the Half-year  Report for the period  1 January to  30 June, 2016. The report is available in Swedish only. Open the full report For more information please contact: Jan Alenfall, CEO Phone: +46 (0)46 19 21 97 Email: info@follicum.com